Edward Lanphier - Sangamo Therapeutics President CEO, Director
| SGMO Stock | USD 0.52 0.01 1.96% |
CEO
Mr. Edward O. Lanphier II, is NonExecutive Chairman of the Board of the Company. He was President, Chief Executive Officer, Director of Sangamo BioSciences, Inc. Mr. Lanphier has over 30 years of experience in the pharmaceutical and biotechnology industry. From June 1992 to May 1997, he held various positions at Somatix Therapy Corporationrationration, a gene therapy company, including Executive Vice President, Commercial Development and Chief Financial Officer. Prior to Somatix, Mr. Lanphier was President and Chief Executive Officer of BioGrowth, Inc., a biotechnology company that merged with Celtrix Laboratories to form Celtrix Pharmaceuticals, Inc. in 1991. From 1986 to 1987, Mr. Lanphier served as Vice President of Corporationrationrate Development at Biotherapeutics, Inc. From 1984 to 1986 he served as Vice President of Corporationrationrate Development at Synergen Inc. Prior to Synergen, he was employed by Eli Lilly and Company, a pharmaceutical company, in the strategic business planning biotechnology group. He currently serves on the board of directors of the Biotechnology Institute, the board of directors and as a member of the Executive Committee of the Alliance for Regenerative Medicine, the board of trustees for The Buck Institute for Research on Aging and the Deans Advisory Board of the University of Michigan School of Public Health. Mr. Lanphier received a B.A. in biochemistry from Knox College. Mr. Lanphier brings extensive experience in executive management of biotechnology companies focused on the therapeutic development of biologics. In addition, Mr. Lanphiers day to day leadership and intimate knowledge of Sangamos business and operations provide the Board with an indepth understanding of the Company. since 2016.
| Age | 57 |
| Tenure | 8 years |
| Address | 501 Canal Blvd, Richmond, CA, United States, 94804 |
| Phone | 510-970-6000 |
| Web | https://www.sangamo.com |
Sangamo Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.176) % which means that it has lost $0.176 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.3647) %, meaning that it created substantial loss on money invested by shareholders. Sangamo Therapeutics' management efficiency ratios could be used to measure how well Sangamo Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 24th of April 2024, Return On Tangible Assets is likely to grow to -1.48. In addition to that, Return On Capital Employed is likely to grow to -0.92. At this time, Sangamo Therapeutics' Asset Turnover is very stable compared to the past year.Similar Executives
| Found 3 records | CEO Age | ||
| Geoffrey MacKay | AVROBIO | N/A | |
| Robert Foster | Hepion Pharmaceuticals | N/A | |
| Geoff MacKay | AVROBIO | 50 | |
Management Performance
| Return On Equity | -1.36 | ||||
| Return On Asset | -0.18 |
Sangamo Therapeutics Leadership Team
Elected by the shareholders, the Sangamo Therapeutics' board of directors comprises two types of representatives: Sangamo Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sangamo. The board's role is to monitor Sangamo Therapeutics' management team and ensure that shareholders' interests are well served. Sangamo Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sangamo Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ward Wolff, CFO and Executive VP | ||
| Mark McClung, Ex COO | ||
| Stephanie CLP, Head Management | ||
| Geoffrey Nichol, Executive Vice President - Research and Development | ||
| Prathyusha Durabaibu, Principal Accounting Officer | ||
| Whitney Jones, VP Officer | ||
| Stephen Dilly, Independent Director | ||
| Stephane Boissel, Interim CFO | ||
| John Larson, Independent Director | ||
| Edward Conner, Senior Vice President and Chief Medical Officer | ||
| ChB MB, Pres CEO | ||
| Robert Carey, Independent Director | ||
| McDavid Stilwell, IR Contact Officer | ||
| Heather Erickson, Chief Staff | ||
| Elizabeth Wolffe, IR Contact Officer, Corporate Communications | ||
| Karen Smith, Director | ||
| Nathalie DuboisStringfellow, Senior Officer | ||
| Louise Wilkie, Vice Communications | ||
| Michael Holmes, Senior Vice President CTO | ||
| Stewart Parker, Director | ||
| Jason Fontenot, Senior Vice President Cell Therapy | ||
| Phillip Ramsey, Head Operations | ||
| David Ojala, Scientist Research | ||
| Adrian Woolfson, Executive Vice President of Research and Development | ||
| Alexander Macrae, President CEO, Director | ||
| Andrew Ramelmeier, Ex Operations | ||
| Scott Willoughby, General VP | ||
| Steven Mento, Independent Director | ||
| Heather Turner, Senior Vice President General Counsel | ||
| Gregory Davis, Head Technology | ||
| Curt Herberts, Senior Vice President and Chief Business Officer | ||
| Lisa MD, Chief Officer | ||
| Aron Feingold, Head Officer | ||
| Amy Pooler, Head Research | ||
| Saira Ramasastry, Independent Director | ||
| Edward Lanphier, President CEO, Director | ||
| Roger Jeffs, Director | ||
| Kathy Yi, CFO, Senior Vice President | ||
| William Ringo, Independent Chairman of the Board | ||
| Paul Cleveland, Independent Director | ||
| Edward Rebar, Senior Vice President CTO | ||
| Joseph Zakrzewski, Director | ||
| Dale Ando, Vice President - Therapeutic Development, Chief Medical Officer |
Sangamo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sangamo Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.36 | ||||
| Return On Asset | -0.18 | ||||
| Profit Margin | (1.46) % | ||||
| Operating Margin | (24.76) % | ||||
| Current Valuation | 48.36 M | ||||
| Shares Outstanding | 207.5 M | ||||
| Shares Owned By Insiders | 7.70 % | ||||
| Shares Owned By Institutions | 56.50 % | ||||
| Number Of Shares Shorted | 11.41 M | ||||
| Price To Earning | (15.31) X |
Currently Active Assets on Macroaxis
When determining whether Sangamo Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sangamo Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sangamo Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sangamo Therapeutics Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sangamo Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. To learn how to invest in Sangamo Stock, please use our How to Invest in Sangamo Therapeutics guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Complementary Tools for Sangamo Stock analysis
When running Sangamo Therapeutics' price analysis, check to measure Sangamo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sangamo Therapeutics is operating at the current time. Most of Sangamo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Sangamo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sangamo Therapeutics' price. Additionally, you may evaluate how the addition of Sangamo Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |
Is Sangamo Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sangamo Therapeutics. If investors know Sangamo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sangamo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.48) | Revenue Per Share 1.01 | Quarterly Revenue Growth (0.93) | Return On Assets (0.18) | Return On Equity (1.36) |
The market value of Sangamo Therapeutics is measured differently than its book value, which is the value of Sangamo that is recorded on the company's balance sheet. Investors also form their own opinion of Sangamo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sangamo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sangamo Therapeutics' market value can be influenced by many factors that don't directly affect Sangamo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sangamo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sangamo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sangamo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.